Biogen Inc.

BIIB

$205.99

-1.40%

N/A-$2.93

Healthcare

Drug Manufacturers - General

NASDAQ

Active Trading

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative ...

Recent News of BIIB

Stockhead7/13/2026Somewhat-Bullish (0.205)

Health Check: Immutep shares bounce on revived lung cancer treatment hopes

Immutep (ASX:IMM) shares surged 30% after releasing positive overall survival data from its INSIGHT-003 lung cancer study, offering renewed hope for its eftilagimod alfa treatment. This comes after the previous TACTI-004 trial was discontinued due to a futility analysis. The company plans to unveil more results soon and is investigating why the TACTI-004 trial failed to meet expectations.

MarketBeat7/12/2026Bullish (0.368)

LGT Fund Management Co Ltd. Takes $10.18 Million Position in Enbridge Inc $ENB

LGT Fund Management Co Ltd. has acquired a new stake in Enbridge Inc (NYSE: ENB) during the first quarter, purchasing 187,966 shares valued at approximately $10.18 million. This move is part of a broader trend of significant institutional interest in Enbridge, with major investors like Vanguard and Norges Bank also increasing or initiating positions. Enbridge recently reported strong quarterly earnings of $0.71 per share, exceeding analyst expectations, and declared a quarterly dividend of $0.97 per share, representing an annualized yield of 7.1%.

Biogen7/12/2026Bullish (0.420)

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

New clinical data presented at AAIC 2026 indicates that the LEQEMBI® (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers comparable efficacy and safety to the intravenous (IV) administration for early Alzheimer’s disease. Results showed that once-weekly 500 mg SC-AI achieved similar drug exposure to the approved IV regimen, supporting expectations of similar clinical outcomes. Patient and care partner surveys also demonstrated high satisfaction and convenience with the subcutaneous formulation, reinforcing its potential for long-term disease management.

Quiver Quantitative7/12/2026Bullish (0.416)

Eisai and Biogen Present AAIC 2026 Data Supporting Comparable Efficacy and Safety of LEQEMBI Subcutaneous Autoinjector and IV Dosing in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. presented new data at the Alzheimer’s Association International Conference 2026, demonstrating that their LEQEMBI subcutaneous autoinjector (SC-AI) for early Alzheimer's disease offers comparable efficacy and safety to the intravenous (IV) formulation. The SC-AI formulation provides similar drug exposure and clinical outcomes across patient weight groups, with the added benefit of convenient at-home administration. Patient satisfaction with the subcutaneous option was high, highlighting its potential to improve treatment accessibility and long-term disease management.

ad-hoc-news.de7/11/2026Somewhat-Bullish (0.155)

Argenx stock reflects biotech growth story amid global autoimmune focus

Argenx, a biotech company specializing in antibody-based treatments for autoimmune diseases, is positioned in the high-risk, high-reward segment of global biotech with a dual listing on Euronext Brussels and Nasdaq. The company's focus on precision medicine and long-term care for chronic autoimmune diseases aims to generate recurring revenue streams through its pipeline of antibody engineering programs. Investors monitor clinical trial outcomes, regulatory approvals, and commercialization strategies, balancing these risks with the potential for significant rewards from innovative therapies addressing unmet medical needs.

Biogen Inc.

Recent News of BIIB

Health Check: Immutep shares bounce on revived lung cancer treatment hopes

LGT Fund Management Co Ltd. Takes $10.18 Million Position in Enbridge Inc $ENB

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

Eisai and Biogen Present AAIC 2026 Data Supporting Comparable Efficacy and Safety of LEQEMBI Subcutaneous Autoinjector and IV Dosing in Early Alzheimer’s Disease

Argenx stock reflects biotech growth story amid global autoimmune focus

Health Check: Immutep shares bounce on revived lung cancer treatment hopes

LGT Fund Management Co Ltd. Takes $10.18 Million Position in Enbridge Inc $ENB

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

Eisai and Biogen Present AAIC 2026 Data Supporting Comparable Efficacy and Safety of LEQEMBI Subcutaneous Autoinjector and IV Dosing in Early Alzheimer’s Disease

Argenx stock reflects biotech growth story amid global autoimmune focus

Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up

Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?

Ryoncil revenue hits US$36M in Q4, FY26 total at US$115M

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Biogen Slides as Newly Disclosed Charges Pressure Near-Term Earnings

Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s

LBPH stock reflects Longboard Pharma’s focus on neurology pipeline

X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing

Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen

CervoMed completes enrollment in phase 2a nfvPPA trial

INmune Bio says XPro imaging data at AAIC show early Alzheimer’s brain changes

Inventiva Appoints Three Independent Directors Ahead of Key Lanifibranor Phase

Rep. Maria Elvira Salazar Buys Brookfield Renewable Partners L.P. (NYSE:BEP) Shares

Biogen (BIIB) 2024 Cantor Fitzgerald Global Healthcare Conference Summary

Morgan Stanley Adjusts Price Target Biogen to $222 From $224, Maintains Equalweight Rating

Maria Elvira Salazar Makes Significant Trades in Biogen, Brookfield Renewable, and Salesforce

Biogen Inc. stock underperforms Wednesday when compared to competitors

Maria Elvira Salazar Makes Significant Trades in Biogen, Brookfield Renewable, and Salesforce

Moderna (MRNA) Welcomes Michael McDonnell to Board of Directors

Moderna appoints Michael McDonnell to board; shares retreat from 52-week high

Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms

The Future of Genus Patenting Strategies for Antibodies Post- Amgen

A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $217 to $255

BofA Securities Adjusts Biogen Price Target to $217 From $203

Moderna adds former Biogen CFO to board of directors By Investing.com

Former Biogen CFO Michael McDonnell joins Moderna (NASDAQ: MRNA) board and Audit Committee

Moderna adds former Biogen CFO to board of directors

Moderna Appoints Michael McDonnell to Board of Directors

Moderna adds former Biogen CFO Michael McDonnell to its board

Moderna Appoints Michael McDonnell to Board of Directors

Biogen (BIIB) Q1 2025 earnings summary

Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics

How Investors May Respond To Stoke Therapeutics (STOK) Completing Phase 3 Enrollment For Zorevunersen In Dravet Syndrome

Biogen Inc. stock underperforms Tuesday when compared to competitors

US-Based TA Associates Emerges as Preferred Bidder for approximately $655.5 Million Acquisition of CGBio

Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again

Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative?

Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again

Biogen to Webcast from the Alzheimer's Association International Conference (AAIC) July 14, 2026

Jefferies Adjusts Price Target on Biogen to $255 From $210

Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma

Biogen Inc (MEX:BIIB) Stock Price, Trades & News

Biogen Inc (BIIB) Shares Fall 3.5% -- GF Value Says Still Overva

Biogen Inc (BIIB) Shares Fall 3.5% -- GF Value Says Still Overvalued

Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms